Corporation in Santa Monica, California, estimated that biosimilars could save $44.2 billion by 2024.
Filgrastim is relatively simple: it is a small protein with no attached sugars. Even so, Sandoz presented the FDA with clinical-trial data from 388 people with breast cancer and 174 healthy participants to show that its biosimilar breaks down in the body similarly to the original, and does not provoke an immune response.
The FDA is expected to make a final decision by May. But even as Sandoz prepares to sell its drug in the United States, it is embroiled in a patent fight with Amgen. By US law, Sandoz had to reveal the details of its manufacturing method to Amgen -a provision not present in Europe -so that Amgen could determine whether any of its patents had been violated. Sandoz refused. That is a disheartening precedent, says Paradise. "Here we've got the first biosimilar application and we've already got the manufacturers not working together. " Such concerns loom large among manufacturers, says Nicholson Price, a patent-law specialist at the University of New Hampshire School of Law in Concord. Drug firms often keep their manufacturing methods confidential, and production of complex drugs gives them ample opportunity to file patents on manufacturing techniques or ways of characterizing molecules. "The second company is attempting to feel its way in the dark to what the first company has done, " says Price. "I suspect there are other biosimilars that are being deterred either by specific patents or just the worry that there may be patents lurking out there that they don't know about. "
Even when a biosimilar makes it over these hurdles, it is unclear how consumers will react to a drug that is almost, but not quite, a copy of the original. At the advisory-committee meeting, a number of patient groups expressed support for biosimilars and the promise of relief from high drug prices. But they voiced concerns that biosimilars would be given the same generic names as the drugs they were meant to replace, creating confusion as to whether recipients were getting the original or the copy. Many will be watching the Sandoz drug's approval to see whether the FDA will let it be called filgrastim.
Committee member James Liebmann, an oncologist at the University of Massachusetts in Worcester, reacted to that concern with surprise. "This has been pretty clearly shown to be filgrastim, " he said. "To name it anything else would be misleading. 
BY E W E N C A L L AWAY
A n innovative method could enable biologists to image an entire brain in exquisite molecular detail using an ordinary microscope.
The technique, called expansion microscopy, involves physically inflating biological tissues using a material more commonly found in baby nappies, or diapers. Edward Boyden, a neuroengineer at the Massachusetts Institute of Technology (MIT) in Cambridge, discussed the technique, which he developed with his MIT colleagues Fei Chen and Paul Tillberg, at a conference last month.
Conventional optical microscopes cannot distinguish objects that are closer together than about 200 nanometres. Although superresolution microscopy can discern objects as close together as about 20 nm, they require expensive, specialized equipment, and struggle with thick structures such as sections of brains.
"What we've been trying to do is figure out if we can make everything bigger, " Boyden told the meeting at the US National Institutes of Health (NIH) in Bethesda, Maryland. To do this, his team used a chemical called sodium acrylate, which has two useful properties: it can form a dense mesh that holds proteins in place, and it swells in the presence of water. The acrylate is the same substance that gives nappies their sponginess. When inflated, Boyden's tissues grow by a factor of about 4.5 in each dimension.
Before swelling, the tissue is treated with a chemical cocktail that makes it transparent, and then with fluorescent molecules that anchor specific proteins to the acrylate, which is then infused into the tissue. Just as with nappies, adding water causes the acrylate to swell. After stretching, the fluorescent-tagged molecules move farther away from each other; proteins that were previously too close to distinguish with a visible-light microscope come into crisp focus. In his presentation, Boyden suggested that the technique can resolve molecules that are as close as 60 nm before expansion.
Crucially, the process generally maintains the relative orientation and interconnection of proteins and keeps other cellular structures intact: it distorts the relative position of proteins by just 1-4%, Boyden's team calculated.
Viviana Gradinaru, a neuroscientist at the California Institute of Technology in Pasadena, says that Boyden's technique is another example of how scientists are bypassing hardware limitations by modifying biological tissue.
"This is certainly highly ingenious, but how much practical use it will be is less clear, " notes Guy Cox, a microscopy specialist at the University of Sydney, Australia. "If this is to be of any serious use, I suspect it will be in collaboration with existing super-resolution techniques on small macromolecular complexes, to push the boundaries a bit further, rather than looking at whole cells. " ■ MAXUSER/SHUTTERSTOCK NENG GONG ET AL./CURR. BIOL.
